The Latest Cardiac and Vascular News
Designation underscores the potential for VS-041 to address a significant unmet medical need and potentially improve diagnosis by utilizing a serum biomarker VS-041 is being evaluated in a Phase 1c study of participants with HFpEF and elevated serum endotrophin ENCINITAS, Calif., and…
Phase 1c Clinical Trial to Begin Immediately ENCINITAS, Calif. and WROCLAW, Poland, Oct. 13, 2025 /PRNewswire/ — Vasa Therapeutics, (“Vasa”), a private, clinical stage biotechnology company developing novel therapies for cardiovascular and metabolic aging, today announced that the U.S….
VS-041 safe and well tolerated in healthy patients Biomarker trial in patients with HFpEF targeted to initiate in 2025 ENCINITAS, Calif. and WROCLAW, Poland, June 4, 2025 /PRNewswire/ — Vasa Therapeutics (“Vasa”), a clinical stage biopharmaceutical company developing novel therapies for…
Vasa Therapeutics granted MHRA Clinical Trial Authorization (CTA) for VS-041 for the treatment of heart failure with preserved ejection fraction (HFpEF) Company’s seed funding extended to $11M ENCINITAS, Calif. and WROCLAW, Poland, Sept. 3, 2024 /PRNewswire/ — Vasa Therapeutics (“Vasa”),…
$6M early-stage biotech investment supplemented by $2.3M non-dilutive grant funding ENCINITAS, Calif., Jan. 3, 2024 /PRNewswire/ — Vasa Therapeutics, Inc. (“Vasa”), a preclinical stage biopharmaceutical company developing novel therapies for cardiovascular aging, announced today the…
